Optimization of the diffusion-weighted MRI processing pipeline for the longitudinal assessment of the brain microstructure in a rat model of Alzheimer’s disease

Tese de mestrado integrado, Engenharia Biomédica e Biofísica (Radiações em Diagnóstico e Terapia) Universidade de Lisboa, Faculdade de Ciências, 2019The mechanism that triggers Alzheimer’s disease (AD) is not well-established, with amyloid plaques, neurofibrillary tangles of tau protein, microgliosis and glucose hypometabolism all likely involved in the early cascade. One main advantage of animal models is the possibility to tease out the impact of each insult on the neurodegeneration. Following an intracerebroventricular (icv) injection of streptozotocin (STZ), rats and monkeys develop impaired brain glucose metabolism, i.e. “diabetes of the brain”. Nu-merous studies have reported AD-like features in icv-STZ animals, but this model has never been char-acterized in terms of Magnetic Resonance Imaging (MRI)-derived biomarkers beyond structural brain atrophy. White matter degeneration has been proposed as a promising biomarker for AD that well pre-cedes cortical atrophy and correlates strongly with disease severity. Therefore, this project proposes a longitudinal study of white matter degeneration in icv-STZ rats using diffusion MRI. An existing image processing pipeline was primarily used to obtain preliminary results and propose an optimization strat-egy to improve it in terms of data quality and reliability. These strategies were tested and implemented in the pipeline when confirmed to be valuable, in order to achieve results as reproducible as possible and find the spatio-temporal pattern of brain degeneration in this animal model. All experiments were approved by the local Service for Veterinary Affairs. Male Wistar rats (N=18) (236±11 g) underwent a bilateral icv-injection of either streptozotocin (3 mg/kg, STZ group, N=10) or buffer (control group, CTL, N=8). Rats were scanned at four timepoints following surgery on a 14 T Varian system. Diffusion data were acquired using a semi-adiabatic SE-EPI PGSE sequence as follows: 4 (b=0 ms/μm2), 12 (b=0.8 ms/μm2), 16 (b=1.3 ms/μm2) and 30 (b=2 ms/μm2) directions; TE/TR=48/2500 ms, 9 coronal 1 mm slices, δ/Δ=4/27 ms, FOV=23x17 mm2, matrix=128x64 and 4 shots. The existing image processing pipeline included image denoising and eddy-correction. Moreover, diffusion and kurtosis tensors were calculated for each voxel, producing parametric maps of fractional anisotropy (FA), mean, axial and radial diffusivity (MD, AxD and RD) and mean, axial and radial kur-tosis (MK, AK and RK). Additionally, the two-compartment WMTI-Watson model was further esti-mated to provide specificity to the microstructure assessment. The following metrics were derived from the model: volume water fraction , parallel intra-axonal diffusivity , parallel ,║ and perpendicular extra-axonal diffusivities ,ꓕ and dispersion of fiber orientations 2. Since the model allows for two mathematical solutions, the >,║ solution was retained based on recent evidence. Considering pre-vious findings, the corpus callosum, cingulum, fornix and fimbria were chosen as white matter regions of interest (ROIs) and automatically segmented using anatomical atlas-based registration. Mean diffu-sion metrics were calculated in each ROI for each dataset. CTL and STZ groups were compared using two-sided t-tests at each timepoint. Within-group longitudinal changes were assessed using one-way ANOVA. Because of the small cohort, statistical analysis excluded the last time point. In the course of this project, strategies to optimize the existing pipeline were developed and tested. The existing brain atlas template was supplemented with white matter labels, rat brain extraction was semi-automated, and bias field correction of anatomical data was added before registration. Ventricle enlargement is typically reported in icv-STZ animals and normally constitutes an issue of misalignment in registration. In order to better match the label ROIs with the respective underlying tissue, several registration procedures were tested with different FA and color-coded FA template images. Color-coded FA-based registration dramatically improved the segmentation of the corpus callosum and the fimbria and reliability of diffusion metrics extracted from these regions. Moreover, additional fiber metrics were extracted from a newly developed tractography pipeline to compare with tensors metrics and finally, tensors metrics were evaluated in the gray matter for a more comprehensive spatio-temporal character-ization of brain degeneration. Results from statistical analysis were obtained after implementing the successful optimization strat-egies into the pipeline. There were few significant differences within groups over time. However, be-tween-group differences at each time point were more pronounced. White matter microstructure altera-tions were consistent with previous studies of histology and cognitive performance of the icv-STZ model. Changes in tensors metrics indicate early axonal injury in the fimbria and fornix at 2 weeks after injection, a period of potential recovery at 6 weeks after injection and late axonal injury at 13 weeks in all ROIs. The WMTI-Watson biophysical model provided specificity to the underlying microstructure, by showing intra-axonal damage in the fimbria and corpus callosum as early as 2 weeks, followed by a recover period and definite axonal loss at 13 weeks after injection. Results from tensors metrics and the WMTI-Watson model are not only complementary, they are consistent with each other and with previously-established trends for structural thickness, memory per-formance, amyloid deposition and inflammation. The icv-STZ model displays white matter changes in tracts reportedly affected by AD, while the degeneration is induced primarily by impaired brain glucose metabolism. The icv-STZ constitutes an excellent model to reproduce sporadic AD and should allow to further explore the hypothesis of AD being “type III diabetes”. The combination of diffusion information extracted from tensor imaging and biophysical modelling is a promising set of tools to assess white matter in the AD brain and might be the upcoming strategy to assess the human brain. Regarding future work, it will focus on estimating the correlation between microstructural alterations and functional con-nectivity (from resting-state functional MRI), glucose hypometabolism (from FDG-PET), and patholog-ical features (from histological stainings) – all currently under processing at CIBM. Tractography is a cutting-edge methodology to assess brain connectivity and the pipeline created could be further devel-oped to improve understanding and support diffusion metrics. The relationship between white and gray matter will also improve the understanding of spatio-temporal degeneration and the progression nature of the disease.O mecanismo que desencadeia a doença de Alzheimer (DA) não é bem conhecido, contudo sabe-se que a presença de placas amilóides e de emaranhados neurofibrilares da proteína tau, microgliose e ainda hipometabolismo de glucose estão envolvidos na fase inicial da cascata de desenvolvimento da doença. A principal vantagem dos modelos animais é justamente a possibilidade de estudar individualmente o impacto de cada um destes mecanismos no processo de neurodegeneração. Após uma injeção intracere-broventricular (icv) de estreptozotocina (STZ), várias espécies de animais mostraram um metabolismo anormal de glucose no cérebro, processo que foi referido como “diabetes do cérebro”. Vários estudos demonstraram que animais icv-STZ são portadores de características típicas de DA, mas este modelo animal nunca foi estudado em termos de biomarcadores derivados de técnicas de imagem por ressonân-cia magnética (IRM), exceto atrofia estrutural do cérebro. Um biomarcador promissor de DA que se acredita preceder a atrofia do córtex cerebral é a degeneração da matéria branca do cérebro, uma vez que foi fortemente correlacionado com a progressão e gravidade da doença. Logo, este projeto propõe um estudo longitudinal da degeneração da matéria branca em ratazanas icv-STZ utilizando IRM de di-fusão. O plano de processamento de imagem existente foi utilizado primeiramente para obter resultados preliminares e viabilizar a proposta de estratégias de otimização da mesma, em termos de melhoramento da qualidade de imagem e credibilidade das variáveis extraídas das imagens resultantes. Estas estratégias foram testadas e implementadas no plano de processamento quando a sua performance confirmou ser de valor, para que os resultados fossem o mais reproduzíveis possível em caracterizar a distribuição espácio-temporal da degeneração do cérebro neste modelo animal. Todos os procedimentos aqui descritos foram aprovados pelo serviço local dos assuntos veterinários. Ratazanas macho Wistar (N=18, 236±11 g) foram submetidas a uma injeção icv de STZ (3 mg/kg) no caso do grupo infetado (N=10) ou de um buffer no caso do grupo de controlo (N=8). As ratazanas foram examinadas no scanner de IRM do tipo Varian de 14 T em quatro momentos no tempo: 2, 6, 13 e 21 semanas após a injeção. As imagens por difusão foram adquiridas com uma sequência semi-adiabática spin-echo EPI PGSE com os seguintes parâmetros: 4 (b=0), 12 (b=0.8 ms/μm2), 16 (b=1.3 ms/μm2) and 30 (b=2 ms/μm2) direções; TE/TR=48/2500 ms, 9 secções coronais de 1 mm, δ/Δ=4/27 ms, FOV=23x17 mm2, matriz=128x64 e 4 shots. O plano existente de processamento de imagem incluía a correção das imagens ao nível de ruído e correntes-eddy. Posteriormente, os tensores de difusão e curtose foram estimados para cada voxel e os mapas paramétricos de anisotropia fracional (FA), difusão média, axial e radial (MD, AD e RD) e cur-tose média, axial e radial (MK, AK e RK) foram calculados. Adicionalmente, um modelo de difusão de água nas fibras da matéria branca foi utilizado para providenciar maior especificidade ao estudo da microestrutura do cérebro. Como tal, o modelo de dois compartimentos denominado WMTI-Watson foi também estimado e as seguintes variáveis foram derivadas do mesmo: a fração do volume de água , a difusividade paralela intra-axonal , as difusividades paralela ,║ e perpendicular ,ꓕ extra-axonais e, finalmente, a orientação da dispersão axonal 2. Este modelo matemático tem duas soluções possíveis dada a sua natureza quadrática, pelo que a solução >,║ foi imposta com base em evidências re-centes. Considerando estudos anteriores, as regiões de interesse (RDIs) da matéria branca escolhidas para analisar a microestrutura cerebral foram o corpo caloso, o cíngulo, a fimbria e a fórnix. Estes foram automaticamente segmentados através de registo de imagem de um atlas das regiões do cérebro da rata-zana e as médias das medidas extraídas dos tensores de difusão e curtose e ainda do modelo biofísico neuronal foram calculadas em cada RDI para cada conjunto de imagens obtidas. Os dois grupos de teste e controlo foram comparados usando testes t de Student bilaterais em cada momento do tempo, e a comparação das alterações longitudinais em cada grupo foi feita usando uma ANOVA. Devido ao baixo número de amostras, o último momento no tempo às 21 semanas foi excluído da análise. No decorrer deste projeto, várias estratégias para otimizar o processamento de imagem ou comple-mentar a análise da informação disponível foram testadas. Nomeadamente, o atlas cerebral da ratazana foi aperfeiçoado relativamente às regiões de matéria branca, a segmentação do cérebro foi testada com algoritmos automáticos e a correção do bias field em imagens estruturais de IRM foi adicionada ao plano antes do registo de imagem. O aumento dos ventrículos cerebrais é uma característica frequente em animais icv-STZ, constituindo um problema de alinhamento nos métodos de registo de imagem. No sentido de otimizar a correspondência entre as regiões do atlas e as respetivas regiões na imagem estru-tural e por difusão, vários procedimentos de registo de imagem foram testados. O co-registo de imagem convencional utiliza imagens estruturais para normalizar o espaço das imagens por difusão, no entanto os mapas paramétricos de FA têm vindo a substituir este conceito dado o excelente contraste que provi-denciam entre a matéria branca e cinzenta do cérebro. Mapas de FA com diferentes direções predomi-nantes mostraram uma melhoria significante da segmentação do corpo caloso e da fimbria e também do poder estatístico das variáveis extraídas destas RDIs. Adicionalmente, um novo plano de processamento de tratografia foi construído de raiz no âmbito deste projeto para extrair variáveis adicionais das fibras de interesse e compará-las com as variáveis de difusão obtidas por análise voxel-a-voxel. Por último, as variáveis calculadas através dos tensores de difusão e curtose foram avaliadas na matéria cinzenta do cérebro para uma caracterização espácio-temporal da degeneração cerebral na DA. Os resultados da análise estatística foram obtidos após integrar no plano de processamento as estra-tégias que mostraram valorizar o projeto em termos de qualidade de imagem ou credibilidade das vari-áveis. Houve poucas diferenças significativas ao longo do tempo em cada grupo, no entanto as diferen-ças entre grupos foram bastante acentuadas. As alterações ao nível da microestrutura da matéria branca foram consistentes com estudos prévios em animais icv-STZ usando métodos histológicos e avaliações das suas capacidades cognitivas. Alterações nas variáveis extraídas dos tensores indicaram deficiência axonal inicial na fimbria e no fórnix 2 semanas após injeção no grupo de teste, um potencial período de recuperação às 6 semanas e novamente deficiência axonal às 13 semanas, sendo que neste período tardio todas as RDIs foram afetadas. O modelo biofísico WMTI-Watson confirmou aumentar especificidade ao estudo da microestrutura, visto que demostrou danos intra-axonais na fimbria e no corpo caloso 2 semanas após injeção, seguidos de um período de recuperação e de perda de estrutura axonal definitiva às 13 semanas em todas as RDIs. Não só estes dois métodos de análise de IRM de difusão se complementam, como são também con-sistentes entre eles e com as tendências de alterações ao longo do tempo descritas noutros estudos. Além disso, o animal icv-STZ mostrou alterações características da DA, mesmo tendo a degeneração cerebral sido induzida pela disrupção do metabolismo de glucose no cérebro. Como tal, este modelo animal é excelente para reproduzir a doença e deverá continuar a ser avaliado nas diferentes áreas multidiscipli-nares para explorar a hipótese de a DA ser desencadeada pela falha do sistema insulina/glucose. A com-binação da informação de difusão obtida dos tensores e da modelação da difusão neuronal provou ser uma ferramenta promissora no estudo das fibras da matéria branca do cérebro e poderá vir a ser o desafio futuro no que toca a investigação clínica da DA. Este estudo focar-se-á em correlacionar as alterações microestruturais aqui descritas com dados de conectividade funcional (obtida por IRM funcional em repouso), hipometabolismo de glucose (por FDG-PET) e outras características patológicas (por colora-ção histológica) – todos já em curso no CIBM. Tratografia é a metodologia topo de gama para aceder à conetividade cerebral e o plano de processamento gerado neste projeto poderá continuar a ser desenvol-vido no futuro para informação adicional, assim como a relação entre a matéria branca e cinzenta poderá suplementar a compreensão da progressão da doença no espaço e no tempo

Oral anticoagulants: A plausible new treatment for Alzheimer's disease?

Alzheimer's disease (AD) and cardiovascular disease (CVD) are strongly associated. Both are multifactorial disorders with long asymptomatic phases and similar risk factors. Indeed, CVD signatures such as cerebral microbleeds, micro-infarcts, atherosclerosis, cerebral amyloid angiopathy and a procoagulant state are highly associated with AD. However, AD and CVD co-development and the molecular mechanisms underlying such associations are not understood. Here, we review the evidence regarding the vascular component of AD and clinical studies using anticoagulants that specifically evaluated the development of AD and other dementias. Most studies reported a markedly decreased incidence of composite dementia in anticoagulated patients with atrial fibrillation, with the highest benefit for direct oral anticoagulants. However, sub-analyses by differential dementia diagnosis were scarce and inconclusive. We finally discuss whether anticoagulation could be a plausible preventive/therapeutic approach for AD and, if so, which would be the best drug and strategy to maximize clinical benefit and minimize potential risks.R. Toribio-Fernandez and M. Cortes-Canteli were supported by a Sara Borrell (CD20/00110) and Miguel Servet type II (CPII21/00007) research contracts from Instituto de Salud Carlos III co-funded by the European Union (Fondo Social Europeo Plus), respectively. C. Tristao-Pereira was supported by a la Caixa Foundation predoctoral fellowship (ID 100010434, LCF/BQ/DI19/11730052) and C. Ceron by a predoctoral fellowship from Fundación Española de Trombosis y Hemostasia (FETH-SETH). The CNIC is a Severo Ochoa Center of Excellence (CEX2020-001041-S).S

Longitudinal interplay between subclinical atherosclerosis, cardiovascular risk factors, and cerebral glucose metabolism in midlife: results from the PESA prospective cohort study.

BACKGROUND Cardiovascular disease and dementia often coexist at advanced stages. Yet, longitudinal studies examining the interplay between atherosclerosis and its risk factors on brain health in midlife are scarce. We aimed to characterise the longitudinal associations between cerebral glucose metabolism, subclinical atherosclerosis, and cardiovascular risk factors in middle-aged asymptomatic individuals. METHODS The Progression of Early Subclinical Atherosclerosis (PESA) study is a Spanish longitudinal observational cohort study of 4184 asymptomatic individuals aged 40-54 years (NCT01410318). Participants with subclinical atherosclerosis underwent longitudinal cerebral [18F]fluorodeoxyglucose ([18F]FDG)-PET, and annual percentage change in [18F]FDG uptake was assessed (primary outcome). Cardiovascular risk was quantified with SCORE2 and subclinical atherosclerosis with three-dimensional vascular ultrasound (exposures). Multivariate regression and linear mixed effects models were used to assess associations between outcomes and exposures. Additionally, blood-based biomarkers of neuropathology were quantified and mediation analyses were performed. Secondary analyses were corrected for multiple comparisons using the false discovery rate (FDR) approach. FINDINGS This longitudinal study included a PESA subcohort of 370 participants (median age at baseline 49·8 years [IQR 46·1-52·2]; 309 [84%] men, 61 [16%] women; median follow-up 4·7 years [IQR 4·2-5·2]). Baseline scans took place between March 6, 2013, and Jan 21, 2015, and follow-up scans between Nov 24, 2017, and Aug 7, 2019. Persistent high risk of cardiovascular disease was associated with an accelerated decline of cortical [18F]FDG uptake compared with low risk (β=-0·008 [95% CI -0·013 to -0·002]; pFDR=0·040), with plasma neurofilament light chain, a marker of neurodegeneration, mediating this association by 20% (β=0·198 [0·008 to 0·740]; pFDR=0·050). Moreover, progression of subclinical carotid atherosclerosis was associated with an additional decline in [18F]FDG uptake in Alzheimer's disease brain regions, not explained by cardiovascular risk (β=-0·269 [95% CI -0·509 to -0·027]; p=0·029). INTERPRETATION Middle-aged asymptomatic individuals with persistent high risk of cardiovascular disease and subclinical carotid atherosclerosis already present brain metabolic decline, suggesting that maintenance of cardiovascular health during midlife could contribute to reductions in neurodegenerative disease burden later in life. FUNDING Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III, Santander Bank, Pro-CNIC Foundation, BrightFocus Foundation, BBVA Foundation, "la Caixa" Foundation.Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III, Santander Bank, Pro-CNIC Foundation, BrightFocus Foundation, BBVA Foundation, “la Caixa” Foundation. We thank the PESA participants and the imaging, administrative, and medical PESA teams. The PESA study is equally co-funded by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and Santander Bank (Madrid, Spain) and also receives funding from the Instituto de Salud Carlos III (ISCIII), Madrid, Spain (PI15/02019), the European Regional Development Fund (ERDF—A Way to Build Europe), and the European Social Fund (ESF—Investing in Your Future). CNIC is a Severo Ochoa Center of Excellence (CEX2020- 001041-S) and is supported by the ISCIII, the Spanish Ministry for Science and Innovation, and the Pro-CNIC Foundation. CT-P was supported by a “la Caixa” Foundation fellowship (ID 100010434, LCF/BQ/DI19/11730052). MC-C was supported by a Miguel Servet type II research contract (ISCIII, CPII21/00007) and the Fondo de Investigación Sanitaria (ISCIII, PI20/00819). We acknowledge the Sephardic Foundation on Aging and other donors of the Alzheimer’s Disease Research (grant number A2022034S), a programme of the BrightFocus Foundation, for support of this research. This work was also partially produced with the support of a 2021 Leonardo Grant for Researchers and Cultural Creators from the BBVA Foundation awarded to MC-C (the Foundation takes no responsibility for the opinions, statements, and contents of this project, which are entirely the responsibility of its authors). BI was supported by the European Research Council (ERC-2018-CoG 819775-MATRIX). MS is supported by the Knut and Alice Wallenberg Foundation (Wallenberg Centre for Molecular and Translational Medicine; KAW2014.0363), the Swedish Research Council (2017-02869, 2021-02678, 2021-06545), the Swedish state under the agreement between the Swedish Government and the County Councils, the ALF-agreement (ALFGBG-813971, ALFGBG-965326), the Swedish Brain Foundation (FO2021-0311), and the Swedish Alzheimer Foundation (AF-740191). MS-C receives funding from the European Research Council (grant agreement number 948677), project “PI19/00155”, funded by ISCIII and co-funded by the EU, and a fellowship from “la Caixa” Foundation (ID 100010434) and from the EU’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement number 847648 (LCF/BQ/PR21/11840004). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018), the EU’s Horizon Europe research and innovation programme under grant agreement number 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation, USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the EU’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement number 860197 (MIRIADE), the EU Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017-00915, #2022-00732), the Swedish state under the agreement between the Swedish Government and the County Councils, the ALFagreement (#ALFGBG-715986, #ALFGBG-965240), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270), Hjärnfonden, Sweden (#FO2017-0243, #ALZ2022-0006), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), and the Alzheimer’s Association 2022–2025 grant (SG-23-1038904 QC).S

Longitudinal interplay between subclinical atherosclerosis, cardiovascular risk factors, and cerebral glucose metabolism in midlife: results from the PESA prospective cohort study

BACKGROUND: Cardiovascular disease and dementia often coexist at advanced stages. Yet, longitudinal studies examining the interplay between atherosclerosis and its risk factors on brain health in midlife are scarce. We aimed to characterise the longitudinal associations between cerebral glucose metabolism, subclinical atherosclerosis, and cardiovascular risk factors in middle-aged asymptomatic individuals. METHODS: The Progression of Early Subclinical Atherosclerosis (PESA) study is a Spanish longitudinal observational cohort study of 4184 asymptomatic individuals aged 40-54 years (NCT01410318). Participants with subclinical atherosclerosis underwent longitudinal cerebral [18F]fluorodeoxyglucose ([18F]FDG)-PET, and annual percentage change in [18F]FDG uptake was assessed (primary outcome). Cardiovascular risk was quantified with SCORE2 and subclinical atherosclerosis with three-dimensional vascular ultrasound (exposures). Multivariate regression and linear mixed effects models were used to assess associations between outcomes and exposures. Additionally, blood-based biomarkers of neuropathology were quantified and mediation analyses were performed. Secondary analyses were corrected for multiple comparisons using the false discovery rate (FDR) approach. FINDINGS: This longitudinal study included a PESA subcohort of 370 participants (median age at baseline 49·8 years [IQR 46·1-52·2]; 309 [84%] men, 61 [16%] women; median follow-up 4·7 years [IQR 4·2-5·2]). Baseline scans took place between March 6, 2013, and Jan 21, 2015, and follow-up scans between Nov 24, 2017, and Aug 7, 2019. Persistent high risk of cardiovascular disease was associated with an accelerated decline of cortical [18F]FDG uptake compared with low risk (β=-0·008 [95% CI -0·013 to -0·002]; pFDR=0·040), with plasma neurofilament light chain, a marker of neurodegeneration, mediating this association by 20% (β=0·198 [0·008 to 0·740]; pFDR=0·050). Moreover, progression of subclinical carotid atherosclerosis was associated with an additional decline in [18F]FDG uptake in Alzheimer's disease brain regions, not explained by cardiovascular risk (β=-0·269 [95% CI -0·509 to -0·027]; p=0·029). INTERPRETATION: Middle-aged asymptomatic individuals with persistent high risk of cardiovascular disease and subclinical carotid atherosclerosis already present brain metabolic decline, suggesting that maintenance of cardiovascular health during midlife could contribute to reductions in neurodegenerative disease burden later in life. FUNDING: Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III, Santander Bank, Pro-CNIC Foundation, BrightFocus Foundation, BBVA Foundation, "la Caixa" Foundation

Walking the talk for dementia: a unique immersive, embodied, and multi‐experiential initiative

Coping with dementia requires an integrated approach encompassing personal, health, research, and community domains. Here we describe “Walking the Talk for Dementia,” an immersive initiative aimed at empowering people with dementia, enhancing dementia understanding, and inspiring collaborations. This initiative involved 300 participants from 25 nationalities, including people with dementia, care partners, clinicians, policymakers, researchers, and advocates for a 4-day, 40 km walk through the Camino de Santiago de Compostela, Spain. A 2-day symposium after the journey provided novel transdisciplinary and horizontal structures, deconstructing traditional hierarchies. The innovation of this initiative lies in its ability to merge a physical experience with knowledge exchange for diversifying individuals' understanding of dementia. It showcases the transformative potential of an immersive, embodied, and multi-experiential approach to address the complexities of dementia collaboratively. The initiative offers a scalable model to enhance understanding, decrease stigma, and promote more comprehensive and empathetic dementia care and research

Synchronous nonmonotonic changes in functional connectivity and white matter integrity in a rat model of sporadic Alzheimer's disease

Brain glucose hypometabolism has been singled out as an important contributor and possibly main trigger to Alzheimer's disease (AD). Intracerebroventricular injections of streptozotocin (icv-STZ) cause brain glucose hypometabolism without systemic diabetes. Here, a first-time longitudinal study of brain glucose metabolism, functional connectivity and white matter microstructure was performed in icv-STZ rats using PET and MRI. Histological markers of pathology were tested at an advanced stage of disease. STZ rats exhibited altered functional connectivity and intra-axonal damage and demyelination in brain regions typical of AD, in a temporal pattern of acute injury, transient recovery/compensation and chronic degeneration. In the context of sustained glucose hypometabolism, these nonmonotonic trends – also reported in behavioral studies of this animal model as well as in human AD – suggest a compensatory mechanism, possibly recruiting ketone bodies, that allows a partial and temporary repair of brain structure and function. The early acute phase could thus become a valuable therapeutic window to strengthen the recovery phase and prevent or delay chronic degeneration, to be considered both in preclinical and clinical studies of AD. In conclusion, this work reveals the consequences of brain insulin resistance on structure and function, highlights signature nonmonotonic trajectories in their evolution and proposes potent MRI-derived biomarkers translatable to human AD and diabetic populations

Oral anticoagulants: A plausible new treatment for Alzheimer's disease?

Alzheimer's disease (AD) and cardiovascular disease (CVD) are strongly associated. Both are multifactorial disorders with long asymptomatic phases and similar risk factors. Indeed, CVD signatures such as cerebral microbleeds, micro-infarcts, atherosclerosis, cerebral amyloid angiopathy and a procoagulant state are highly associated with AD. However, AD and CVD co-development and the molecular mechanisms underlying such associations are not understood. Here, we review the evidence regarding the vascular component of AD and clinical studies using anticoagulants that specifically evaluated the development of AD and other dementias. Most studies reported a markedly decreased incidence of composite dementia in anticoagulated patients with atrial fibrillation, with the highest benefit for direct oral anticoagulants. However, sub-analyses by differential dementia diagnosis were scarce and inconclusive. We finally discuss whether anticoagulation could be a plausible preventive/therapeutic approach for AD and, if so, which would be the best drug and strategy to maximize clinical benefit and minimize potential risks.R. Toribio-Fernandez and M. Cortes-Canteli were supported by a Sara Borrell (CD20/00110) and Miguel Servet type II (CPII21/00007) research contracts from Instituto de Salud Carlos III co-funded by the European Union (Fondo Social Europeo Plus), respectively. C. Tristao-Pereira was supported by a La Caixa Foundation predoctoral fellowship (ID 100010434, LCF/BQ/DI19/11730052) and C. Ceron by a predoctoral fellowship from Fundación Española de Trombosis y Hemostasia (FETH-SETH). The CNIC is a Severo Ochoa Center of Excellence (CEX2020-001041-S).With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001041-S).Peer reviewe

Contribution of preclinical MRI to responsible animal research: living up to the 3R principle

International audienc

Apolipoprotein E-ε2 and Resistance to Atherosclerosis in Midlife-The PESA Observational Study.

BACKGROUND APOE is a known genetic contributor to cardiovascular disease, but the differential role APOE alleles play in subclinical atherosclerosis remains unclear. METHODS The PESA (Progression of Early Subclinical Atherosclerosis) is an observational cohort study that recruited 4184 middle-aged asymptomatic individuals to be screened for cardiovascular risk and multiterritorial subclinical atherosclerosis. Participants were APOE-genotyped, and omics data were additionally evaluated. RESULTS In the PESA study, the frequencies for APOE -ε2, -ε3, and -ε4 alleles were 0.060, 0.844, and 0.096, respectively. This study included a subcohort of 3887 participants (45.8±4.3 years of age; 62% males). As expected, APOE-ε4 carriers were at the highest risk for cardiovascular disease and had significantly greater odds of having subclinical atherosclerosis compared with ε3/ε3 carriers, which was mainly explained by their higher levels of LDL (low-density lipoprotein)-cholesterol. In turn, APOE-ε2 carriers were at the lowest risk for cardiovascular disease and had significantly lower odds of having subclinical atherosclerosis in several vascular territories (carotids: 0.62 [95% CI, 0.47-0.81]; P=0.00043; femorals: 0.60 [0.47-0.78]; P=9.96×10-5; coronaries: 0.53 [0.39-0.74]; P=0.00013; and increased PESA score: 0.58 [0.48-0.71]; P=3.16×10-8). This APOE-ε2 atheroprotective effect was mostly independent of the associated lower LDL (low-density lipoprotein)-cholesterol levels and other cardiovascular risk factors. The protection conferred by the ε2 allele was greater with age (50-54 years: 0.49 [95% CI, 0.32-0.73]; P=0.00045), and normal (<150 mg/dL) levels of triglycerides (0.54 [0.44-0.66]; P=4.70×10-9 versus 0.90 [0.57-1.43]; P=0.67 if ≥150 mg/dL). Omics analysis revealed an enrichment of several canonical pathways associated with anti-inflammatory mechanisms together with the modulation of erythrocyte homeostasis, coagulation, and complement activation in ε2 carriers that might play a relevant role in the ε2's atheroprotective effect. CONCLUSIONS This work sheds light on the role of APOE in cardiovascular disease development with important therapeutic and prevention implications on cardiovascular health, especially in early midlife. REGISTRATION URL: https://www.clinicaltrials.gov: NCT01410318.The PESA (Progression of Early Subclinical Atherosclerosis) study is cofunded equally by CNIC and Santander Bank, Madrid, Spain and also receives funding from the Instituto de Salud Carlos III (ISCIII), Madrid, Spain (PI15/02019), the European Regional Development Fund (ERDF–A Way to Build Europe), and the European Social Fund (ESF–Investing in Your Future). Dr Toribio-Fernández was supported by Iniciativa de Empleo Juvenil from Consejería de Educación, Juventud y Deporte de la Comunidad de Madrid, Madrid, Spain (PEJD-2018-POST/ BMD-9259) and by a Sara Borrell research contract (ISCIII, CD20/00110; cofunded by the ESF+). C. Tristão-Pereira was supported by a “la Caixa” Foundation fellowship (ID 100010434, LCF/BQ/DI19/11730052) and by an Alzheimer’s Disease Standard Award from BrightFocus Foundation awarded to Dr Cortes-Canteli (A2022034S). Dr Ibanez was supported by the European Research Council (ERC-2018-CoG 819775-MATRIX). Dr Cortes-Canteli was supported by a Miguel Servet type II research contract (ISCIII, CPII21/00007; cofunded by the ESF+), and this study has been funded by ISCIII through the projects PI17/00590 and PI20/00819; cofunded by the European Union. Dr Garcia-Alvarez received funding from the ISCIII (PI20/00742; cofunded by the ERDF). Dr Martin is supported by MCIN-ISCIII-Fondo de Investigación Sanitaria (PI22/01759 cofunded by the ERDF; PMPTA22/00090-BIOCARDIOTOX cofunded by the NextGEN fund) and the Comunidad de Madrid (P2022/BMD7209-INTEGRAMUNE-CM). The CNIC is supported by the ISCIII, the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/ AEI/10.13039/501100011033).S

Subclinical atherosclerosis and brain metabolism in middle-aged individuals: The PESA study

Background: Atherosclerosis has been linked to cognitive decline in late life; however, the impact of cardiovascular risk factors (CVRFs) and subclinical atherosclerosis on brain metabolism at earlier stages remains unexplored. Objectives: This study sought to determine the association between brain metabolism, subclinical atherosclerosis, and CVRFs in middle-aged asymptomatic individuals. Methods: This study included 547 asymptomatic middle-aged participants (50 ± 4 years, 82% men) from the PESA (Progression of Early Subclinical Atherosclerosis) study with evidence of subclinical atherosclerosis. Participants underwent 18F-fluorodeoxyglucose (FDG)-positron emission tomography. Global brain FDG uptake and voxel-wise analyses were used to evaluate the associations of cerebral metabolism with CVRFs and atherosclerotic plaque burden in carotids and femorals assessed by 3-dimensional vascular ultrasound. Results: Global FDG uptake showed an inverse correlation with 30-year Framingham Risk Score (FRS) (β = -0.15, p < 0.001). This association was mainly driven by the presence of hypertension (d = 0.36, p < 0.001). Carotid plaque burden was inversely associated with global brain FDG uptake (β = -0.16, p < 0.001), even after adjusting for 30-year FRS. Voxel-wise approaches revealed that the brain areas most strongly affected by hypometabolism in association with 30-year FRS, hypertension, and carotid plaque burden were parietotemporal regions (angular, supramarginal, and inferior/middle temporal gyri) and the cingulate gyrus. Conclusions: In asymptomatic middle-aged individuals, cardiovascular risk is associated with brain hypometabolism, with hypertension being the modifiable CVRF showing the strongest association. Subclinical carotid plaque burden is also linked to reduced brain metabolism independently of CVRFs. Cerebral areas showing hypometabolism include those known to be affected in dementia. These data reinforce the need to control CVRFs early in life in order to potentially reduce the brain's midlife vulnerability to future cognitive dysfunction.The study also receives funding from the Instituto de Salud Carlos III, Madrid, Spain (ISCIII, PI15/02019), the European Regional Development Fund (ERDF–A Way to Build Europe) and the European Social Fund (ESF–Investing in Your Future). Dr. Cortes-Canteli was supported by a Miguel Servet type I research contract (ISCIII, CP16/00174 & MS16/00174) and the Fondo de Investigación Sanitaria (ISCIII, PI17/00590 & PI20/00819). Dr. Toribio-Fernandez was supported by the Iniciativa de Empleo Juvenil of the Consejería de Educación, Juventud y Deporte de la Comunidad de Madrid (PEJD-2018-POST/BMD-9259). Ms. Tristão-Pereira was supported by a “la Caixa” Foundation fellowship (ID 100010434, LCF/BQ/DI19/11730052). Dr. Gispert is supported by the Ministerio de Ciencia e Innovación (MCIN; RYC-2013-13054) and Dr. B. Ibanez by the European Research Council (ERC-2018-CoG 819775-MATRIX). The CNIC is supported by the ISCIII, the MCIN, and the Pro-CNIC Foundation. The BBRC is mainly funded by the “la Caixa” Foundation (ID 100010434) under agreement LCF/PR/GN17/50300004, the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD under grant agreement 115736, and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 115952. This Joint Undertaking receives support from the European Union Horizon 2020 Research and Innovation Programme and the EFPIA. Dr. Molinuevo has served as a consultant for, sat on advisory boards of, or delivered lectures in symposia sponsored by Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, and ProMIS Neurosciences. Dr. Gispert has given lectures in symposia sponsored by General Electric, Philips, and Biogen. Dr. Sanchez-Gonzalez is a Philips employee. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose